Description
NMS-P953 is a JAK2 inhibitor, displaying significant tumor growth inhibition in SET-?2 xenograft tumor model. NMS-P953 has a mechanism of action confirmed in vivo by typical modulation of known biomarkers, and with a favorable pharmacokinetic and safety profile.
Uses
NMS-P953 (compound 28) is an orally active JAK2 inhibitor (IC50=0.008 μM) with antitumor activity[1].
IC 50
JAK2: 0.008 μM (IC
50)
References
[1] Brasca M G, et al. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors[J]. Bioorganic & Medicinal Chemistry, 2014, 22(17): 4998-5012. DOI:
10.1016/j.bmc.2014.06.025